齐拉西酮与氟伏沙明联合治疗难治性抑郁症的临床对照研究  

Clinical Control Study of Ziprasidone Combined with Fluvoxamine in Treatment of Intractable Depression

作　　者：何俊[1] 

机构地区：[1]杭州市第七人民医院药剂科,浙江杭州310015

出　　处：《中国现代医生》2011年第25期87-88,90,共3页China Modern Doctor

摘　　要：目的探讨齐拉西酮与氟伏沙明联合治疗难治性抑郁症临床治疗效果。方法收集2010年5月～2011年5月来我院就诊的难治性抑郁症患者78例,随机分为对照组和观察组,每组39例。对照组患者单独给予氟伏沙明治疗,观察组患者给予齐拉西酮和氟伏沙明联合治疗,在治疗前和治疗后第2、4、6、8、10、12周采用HAMD、HAMA评定治疗效果,用TESS评定其副作用。结果观察组治疗第2周后HAMD、HAMA评分均显著降低;对照组治疗第4周后HAMD、HAMA评分显著降低。两组治疗第6周后HAMD评分、治疗第4周后HAMA评分比较差异有统计学意义(P<0.05)。观察组治疗有效率明显高于对照组,两组不良反应发生率比较差异无统计学意义(P>0.05)。结论齐拉西酮和氟伏沙明联合使用治疗难治性抑郁症效果较好,且不良反应的发生率较低,可以在临床推广应用。Objective To study the clinical effect of Ziprasidone combined with fluvoxamine in treatment of intractable depression. Methods All 78 cases with intractable depression were selected in our hospital from May 2010 to May 2011, they were divided into observation group （ n=39 ） and control group （ n=39 ） randomly. Control group was given fluvoxamine and observation group was given Ziprasidone combined with Fluvoxamine. The effect before and 2,4,6,8,10, 12 week after the treatment were assessed by HAMD, HAMA, the adverse reaction was assessed by TESS. Results Score of HAMD, HAMA two week after the treatment in the observation group was lower, but those index in the control group were lower four week after the treatment. The HAMD score, HAMA score had significant difference at six and four week after the treatment separately （P 〈 0.05 ） ; The effect rate in the observation group was much higher than that in the control group, there were no difference in the adverse reaction of two groups （ P ~ 0.05 ）. Conclusion Ziprasidone combined with Fluvoxamine in treatment of Intractable depression have good results and low incidence rate of adverse reaction, it is well worth clinical popularizing and application.

关 键 词：难治性抑郁症 齐拉西酮 氟伏沙明 

分 类 号：R749.4[医药卫生—神经病学与精神病学]